DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
+19.07%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$2.81B
AUM Growth
+$2.81B
(-0.26%)
Cap. Flow
-$131M
Cap. Flow
% of AUM
-4.68%
Top 10 Holdings %
Top 10 Hldgs %
28.25%
Holding
132
New
16
Increased
23
Reduced
29
Closed
16
Top Buys
| 1 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
$54.6M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$54.4M |
| 3 |
Tandem Diabetes Care
TNDM
|
$49.7M |
| 4 |
Xeris Biopharma Holdings
XERS
|
$47.4M |
| 5 |
Sarepta Therapeutics
SRPT
|
$39.1M |
Top Sells
| 1 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
$93.4M |
| 2 |
DexCom
DXCM
|
$46M |
| 3 |
Natera
NTRA
|
$39.5M |
| 4 |
Glaukos
GKOS
|
$36.1M |
| 5 |
Centene
CNC
|
$32.5M |
Sector Composition
| 1 | Healthcare | 74.9% |
| 2 | Financials | 2.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MNK
1
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $130M | 4.58% | 6,988,248 -1,633,135 | -19% | -$30.5M |
|
|
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $109M | 3.84% | 6,609,894 | – | – |
|
3
Q32 Bio
QTTB
$20.9M
| $107M | 3.74% | 5,227,035 | – | – |
|
|
MRTX
4
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $64.1M | 2.25% | 1,300,365 +1,103,365 | +560% | +$54.4M |
|
5
Viatris
VTRS
$12.3B
| $63M | 2.21% | 1,742,111 -806,000 | -32% | -$29.1M |
|
|
MYOK
6
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $57.5M | 2.02% | 1,159,000 +90,320 | +8% | +$4.48M |
|
|
7
Tandem Diabetes Care
TNDM
$845M
| $56.7M | 1.99% | 2,573,305 +2,255,305 | +709% | +$49.7M |
|
|
DBVT
8
DBV Technologies
DBVT
$264M
| $55.9M | 1.96% | 2,900,000 | – | – |
|
9
Aclaris Therapeutics
ACRS
$209M
| $54.8M | 1.93% | 2,745,705 | – | – |
|
|
XLRN
10
DELISTED
Acceleron Pharma Inc.
XLRN
| $54.7M | 1.92% | 1,126,800 +511,800 | +83% | +$24.8M |
|
|
PTLA
11
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $54.6M | 1.92% | +1,446,633 | New | +$54.6M |
|
|
12
Xeris Biopharma Holdings
XERS
$1.26B
| $47.4M | 1.67% | +2,498,666 | New | +$47.4M |
|
13
Elevance Health
ELV
$71.8B
| $45.5M | 1.6% | 191,000 | – | – |
|
|
AET
14
DELISTED
Aetna Inc
AET
| $42M | 1.48% | 229,000 +64,000 | +39% | +$11.7M |
|
15
Editas Medicine
EDIT
$231M
| $41.5M | 1.46% | 1,158,841 | – | – |
|
|
BOLD
16
DELISTED
Audentes Therapeutics, Inc
BOLD
| $40.1M | 1.41% | 1,048,430 -336,040 | -24% | -$12.8M |
|
17
AnaptysBio
ANAB
$569M
| $40M | 1.4% | 562,989 -231,349 | -29% | -$16.4M |
|
|
18
Centene
CNC
$14.3B
| $40M | 1.4% | 324,536 -263,464 | -45% | -$32.5M |
|
|
19
Sarepta Therapeutics
SRPT
$1.78B
| $39.1M | 1.37% | +296,000 | New | +$39.1M |
|
|
XENT
20
DELISTED
Intersect ENT, Inc
XENT
| $38.2M | 1.34% | 1,020,000 +187,500 | +23% | +$7.02M |
|
21
argenx
ARGX
$43.6B
| $37M | 1.3% | 447,029 +127,109 | +40% | +$10.5M |
|
22
CVS Health
CVS
$92.8B
| $35.4M | 1.24% | 550,000 | – | – |
|
23
BioCryst Pharmaceuticals
BCRX
$1.74B
| $34.7M | 1.22% | 6,063,496 -1,302,964 | -18% | -$7.47M |
|
24
Select Medical
SEM
$1.61B
| $33.7M | 1.18% | 1,858,000 | – | – |
|
|
AERI
25
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $32.7M | 1.15% | 484,055 | – | – |
|